ECRIN Partners & Collaborations
In 2022 ECRIN officially joined forces with BBMRI (European Research Infrastructure for Biobanking and Biomolecular Resources) & EATRIS (European Research Infrastructure for Translational Medicine) to form the European Alliance of Medical Research Infrastructures (EU-AMRI). EU-AMRI is the collaboration between the three research infrastructures who work in parallel, providing complementary services to researchers in the field of biomedical sciences and who support the development of personalised medicine and new treatments. EU-AMRI has been created to offer a comprehensive workflow for researchers in biomedical science, a one-stop-shop for industry and academia, to conveniently choose from a range of services according to their needs.
In the context of its trial support activities and projects, ECRIN works with multiple partners across Europe. One example is a strategic bilateral partnership with EUPATI, the European Patients’ Academy on Therapeutic Innovation. With this collaboration, both ECRIN and EUPATI wish to elaborate on their commitment to provide and improve education and training opportunities in clinical research for patients and patient representatives. Also, they aim to strengthen academic researchers’ capacities to effectively engage with patients in their studies.
Affiliate and International Partners
ECRIN works with many other partners across the globe. These groups or organisations are typically focused on clinical research in general, or on a specific research area or disease in particular. Located in Europe and internationally, they may be directly involved in ECRIN-supported trials or collaborative projects, or may also simply wish to maintain close contact with ECRIN and support its goals. ECRIN's partners may be designated as affiliate or international partners, depending on the nature of the collaboration and agreement signed (i.e., framework agreement or MoU).
ECRIN also develops a network of certified data centre to provide compliant, effective, and efficient data management services for controlled clinical trials.
Discover the certified ECRIN Data Centres
EVICR.net and ECRIN signed a framework agreement in 2015. EVICR.net is a network of European ophthalmological clinical research sites dedicated to performing the highest quality clinical research. Following European and international directives for clinical research and common standard operating procedures (SOPs), EVICR.net aims to strengthen the capacity of the European Union to study the determinants of ophthalmic diseases and to develop and optimise the use of diagnostic, prevention and treatment strategies in ophthalmology. EVICR.net is an independent European Economic Interest Grouping (EEIG) established in 2010 in accordance with the Council Regulation (EEC) n.º 2137/85. EVICR.net is headquartered in Coimbra, Portugal at the Association for Innovation and Biomedical Research on Light and Image (AIBILI), which acts as the organisation’s coordinating centre.
European and International Partners
The European Patients’ Academy on Therapeutic Innovation (EUPATI) is a multi-stakeholder public-private partnership originally launched by the IMI-EUPATI project (2012-2017) and hosted by the European Patients’ Forum (EPF) from 2017 to 2020. EUPATI is today established as an independent non-profit Foundation in the Netherlands.
EUPATI provides education and training to increase the capacity and capability of patients and patient representatives to understand and meaningfully contribute to medicines research and development, and to improve the availability of medical information for patients and other stakeholders. In addition, EUPATI provides an open-access multilingual Toolbox, that has served more than 5 million users in 13 languages around the world to date.
Read more about the ECRIN patient engagement here.
FBRI and ECRIN signed an MoU in July 2016. FBRI is a Japanese public interest incorporated foundation, which was established in March 2000. Its basic mission is to contribute to the revitalisation of the economy of Kobe city and the Kansai region and the improvement of health/welfare of citizens and the general public. FBRI also aims to ensure higher health care levels in the world through various activities.
KoNECT and ECRIN signed an MoU in April 2015. KoNECT works to foster Korean clinical trial capabilities and advance infrastructure, training and development of clinical trial professionals and R&D in new technologies. KoNECT’s goals align with ECRIN’s mission to promote high-quality, multinational clinical research. The partnership will increase mutual understanding of regulation and ethical requirements, trial management, and funding in Korea and Europe, leading to collaborative clinical trials. KoNECT is a Korean nonprofit organization funded by the Korean government, committed to achieving the status of a global clinical trial hub and a preferred partner for global drug development, ultimately contributing to earlier access of patients to innovative treatments to be developed either in Korea or outside Korea.
The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is focused on accelerating the process of turning research findings and observations into treatments and cures for disease. NCATS does this by developing new approaches and technologies, demonstrating their usefulness and disseminating to the community. NCATS is involved in collaborations with government, academia, industry and nonprofit patient organizations, including ECRIN.
Inaugurated on May 25, 1900 under the name of Federal Serotherapy Institute, FIOCRUZ was given the mission of fighting the great public health problems in Brazil. Today, the institution is responsible for a range of activities which include research development; hospital and ambulatory care services; production of vaccines, drugs, reagents, and diagnostic kits; education and training of human resources; information and communication in the area of health, science and technology; quality control of products and services, and the implementation of social programs. It has over 11,000 employees and health professionals.
Therapeutic Innovation Australia Ltd (TIA) and ECRIN signed an MoU in May 2014. The aim of the partnership is to foster international collaboration on clinical trials between Europe and Australia through the development of shared tools (e.g. on regulation, quality, training and monitoring strategies) and through coordinated support to international trials.
TIA is an Australian not-for-profit company that supports translational health researchers in taking medical research from the laboratory to clinical application. TIA’s national network consists of 45 sites located at universities, medical research organisations, hospitals and clinical networks that enable development of small molecules, biopharmaceuticals, cell therapies and biomarkers. TIA facilitates partnerships between researchers, capability managers and experts in product development from academic and industry sectors.